Whole-Body UVB Irradiation during Allogeneic Hematopoietic Cell Transplantation Is Safe and Decreases Acute Graft-versus-Host Disease  by Kreutz, Marina et al.
Whole-Body UVB Irradiation during Allogeneic
Hematopoietic Cell Transplantation Is Safe and
Decreases Acute Graft-versus-Host Disease
Marina Kreutz1, Sigrid Karrer2, Petra Hoffmann1, Eva Gottfried1, Rolf-Markus Szeimies2, Joachim Hahn1,
Matthias Edinger1, Michael Landthaler2, Reinhard Andreesen1, Miriam Merad3 and Ernst Holler1
Depletion of host Langerhans cells (LCs) prevents cutaneous graft-versus-host disease (GvHD) in mice. We
analyzed whether UVB irradiation is tolerated during the course of human allogeneic hematopoietic cell
transplantation and whether depletion of LCs by broadband UVB could improve GvHD outcome. A total of
17 patients received six whole-body UVB irradiations with 75% of the individually determined minimal
erythemal dose after conditioning with a reduced intensity protocol. LCs, dermal dendritic cells (DCs), and
macrophages were analyzed before and after UVB irradiation by immunohistochemical analysis. Circulating
blood cells and serum factors were analyzed in parallel. In striking contrast to previous data, our irradiation
protocol was well tolerated in all patients. UVB treatment decreased the number of LCs and also affected
dermal DCs. UVB-treated patients also had significantly higher 25-hydroxyvitamin D3 serum levels and higher
numbers of circulating CD4þ FoxP3þ regulatory T cells. Strikingly, nine out of nine patients with complete LC
depletion (o1 LC per field) developed only grade I GvHD or no GvHD up to day 100. Our results strongly
suggest that prophylactic UVB irradiation post transplant is safe and should be further explored as a clinical
strategy to prevent acute (skin) GvHD.
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INTRODUCTION
Allogeneic hematopoietic cell transplantation (allo-HCT) is
a potentially curative treatment for patients with high-risk
leukemia, lymphoma, and myeloma. The success of allo-HCT
is largely based on immunological graft-versus-tumor effects.
This beneficial effect is counterbalanced by graft-versus-host
disease (GvHD), which occurs in 20–75% of transplant re-
cipients. GvHD manifests as inflammation of the skin, liver,
and gut, with the skin being the most frequently affected
organ. Therefore, a major objective in allo-HCT is the
prevention of GvHD.
The importance of recipient dendritic cells (DCs) in
initiating GvH responses has been established in animal
models (Shlomchik et al., 1999; Zhang et al., 2002). Donor
DCs have a supplementary role and are able to augment acute
GvHD through cross-presentation of host tissue (Matte et al.,
2004). We have shown that epidermal DCs, also called
Langerhans cells (LCs), survive the irradiation regimen in mice
that receive allo-HCT (Merad et al., 2002), and that persistent
recipient LCs are sufficient to generate cutaneous GvHD upon
donor lymphocyte infusion in a major mismatch allo-HCT
mouse model (Merad et al., 2004). Similar results were
observed in a minor mismatch allo-HCT model (Durakovic
et al., 2006). However, a new publication states that LCs are
not required for GvHD induction when other host antigen-
presenting cells are present (Li et al., 2011).
During conditioning, chemotherapy or total-body irradia-
tion leads to eradication of the patient’s residual disease and
elimination of host immune cells. However, in humans, LCs
have been shown to survive the conditioning therapy in
significant numbers compared with blood DCs and mono-
cytes (Auffermann-Gretzinger et al., 2002; Fagnoni et al.,
2004; Collin et al., 2006). The persistence of recipient LCs in
the skin of patients who received allo-HCT has been reported
more than 20 years ago (Perreault et al., 1985).
Our studies in mice also showed that exposure to UV light
before donor lymphocyte infusion can deplete remaining host
LCs, induce their replacement with donor-derived LCs, and
improve cutaneous GvHD outcome (Merad et al., 2004).
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Importantly, exposure to UVB light is a potent inhibitor of
cutaneous hypersensitivity response in mice and humans
(Aubin, 2003). The mechanisms that control UVB-induced
immunosuppression remain unclear. In mice, the depletion
of LCs (Toews et al., 1980), modulation of LC antigen-
presenting function via UVB-induced release of immuno-
suppressive soluble factors (Ullrich, 1994; Dai and Streilein,
1997), and the induction of T regulatory cells by UV-exposed
LCs have been implicated in this process (Schwarz et al.,
2004).
Similarly, in humans, low-dose UVB irradiation leads to
LC depletion from the epidermis (Murphy et al., 1993) and
the impairment of LC antigen presentation and allostimu-
latory function (Cooper et al., 1992). UVB exposure also
induces the recruitment of IL-10 secreting immunosuppres-
sive macrophages to the dermis, which may also contribute
to UVB-mediated immunosuppression (Kang et al., 1994). In
addition, soluble factors induced upon UVB exposure, such
as IL-10, cis-urocanic acid, and vitamin D3, have been
shown to directly modulate LC antigen-presentation function
(Ullrich, 1994; Beissert et al., 2001; Penna et al., 2007). 1,25-
dihydroxyvitamin D3, the physiologically active form of
vitamin D3, induces the development of T regulatory cells in
mice (Gorman et al., 2007), and administration of 1,25-
dihydroxyvitamin D3 analog improves autoimmune diabetes
in NOD mice (Gregori et al., 2002).
In this study, we examined whether allo-HCT patients
tolerate prophylactic exposure to UVB at the time of
transplantation, and analyzed a potential effect on (cuta-
neous) GvHD. Our results on the first 17 patients suggest that
UVB therapy can be safely incorporated to the transplanta-
tion regimen and has the potential to improve (cutaneous)
GvHD outcome in patients treated with allo-HCT.
RESULTS
Using a clinically relevant mouse model of allo-HCT, we
have shown that in vivo depletion of LCs by UVC irradiation
prevents cutaneous GvHD (Merad et al., 2004). To analyze
whether prophylactic UVB irradiation is tolerated and can
improve cutaneous GvHD outcome, we irradiated 17 allo-
HCT patients with low-dose UVB starting from day 1 after
transplantation (schematic view see Figure 1a). Patients
received 75% of their individual minimal erythemal dose,
six times every second day. In spite of the older age and the
high-risk group of patients, UVB prophylaxis did not result in
an increased incidence of neutropenic fever or manifest
infections as compared with historical controls. Full donor
engraftment was achieved in 16/17 patients. One chronic
lymphocytic leukemia patient engrafted only partially and
then developed a secondary graft failure. All other patients
showed an uneventful engraftment, the mean time to
recovery of 4500 neutrophil counts was 15 days with a
range of 10 to 28 days. Mean time to recovery of 420,000
platelets was 14 days (range 1027 days). One patient
showed skin toxicity during UVB prophylaxis, most likely due
to concomitant administration of the photosensitizing anti-
fungal drug voriconazole. In all other patients, UVB irradia-
tion was well tolerated and led to a complete depletion of
CD1a-positive LCs in 9 out of 17 patients (Table 1). None of
the patients with complete LC depletion developed a grade II
GvHD up to day 100. Accordingly, the number of CD1aþ
LCs in the epidermis of UVB patients correlated with the
development of acute GvHD grade less than day 100
(Table 1, r¼0.47, P value¼ 0.05). In contrast, five out of
eight patients with incomplete depletion developed GvHD
Xgrade II. Only 2/17 patients (12%) developed acute
cutaneous GvHDXgrade II in contrast to about 45% in
historical controls treated with identical reduced intensity
conditioning regimen. After day 100, the incidence of severe
chronic or delayed acute GvHD did not significantly differ
between both groups, but median time to maximal–severe
GvHD in general was significantly delayed in the group with
complete depletion (Table 1).
In control patients without UVB irradiation, we also found
a decrease in LC numbers around day 14, but this reduction
was not significant when compared with LC numbers before
the conditioning regimen (Figure 1c). However, as we did not
monitor the individual LC numbers of the control group after
conditioning at the day of HCT, it cannot be excluded that
these patients showed differences to the UVB group in the
number of CD1aþ cells at this time point. Figure 1b shows
two representative samples of skin biopsies isolated at
different time points during transplantation. UVB irradiation
decreased the number of LCs in all but one patient; however,
to a variable degree. A complete depletion was found in nine
patients (Figure 1b, patient #9). Incomplete depletion was
found in eight patients (Figure 1b, patient #11). Figure 1d
and e shows the individual course of CD1aþ cells of
patients with complete depletion (Figure 1d) and incomplete
depletion (Figure 1e). Conditioning resulted in a decrease in
CD1aþ cells in seven out of nine patients in the ‘‘complete
depletion’’ group. However, even those patients with high
numbers of CD1aþ cells after conditioning responded with
a complete LC depletion after UVB irradiation. In contrast, in
the group with incomplete depletion, even patients with low
LC numbers before UVB treatment did not respond with a
complete depletion. Therefore, UVB responsiveness and LC
depletion is not only determined by LC numbers before UVB
treatment or responsiveness to conditioning but also seems to
depend on other factors.
CD14þ and CD14þHLA-DRþ dermal antigen-present-
ing cells were not significantly influenced by the conditioning
regimen (Figure 2a and b). However, by day 14 post
transplantation, the number of dermal CD14þ cells dropped
significantly in control patients who did not receive UVB,
whereas it remained unchanged in the UVB group (Figure 2a
and b). CD14–/HLA-DRþ DCs decreased significantly during
conditioning regimen, but their number was not significantly
affected by UVB irradiation (Figure 2c). Finally, the number
of CD3þ T cells or regulatory T cells in the skin was not
affected by the conditioning regimen or by UVB irradiation
(data not shown).
The number of T cells in peripheral blood is reduced to
about 1% of the initial cell number after conditioning. When
we analyzed the reconstitution of blood CD4þ T cells
and regulatory T cells around 5 weeks post transplantation,
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Figure 1. Analysis of skin biopsies: Langerhans cell (LC) depletion. Six whole-body irradiations were given every second day starting from day 1 after allogeneic
hematopoietic cell transplantation (allo-HCT). Control patients received the same conditioning regime but no UVB irradiation. Biopsies were taken before
conditioning (biopsy between day 15 and 7), after conditioning/before transplantation (biopsy day1/0), and after UVB exposure (biopsy between day þ 10
and þ 15) (a) Skin biopsies were analyzed by immunohistochemical staining. (b) CD1a expression of two representative samples (patient #9, #11;
bar¼ 100 mm). (c) The mean absolute numbers of CD1aþ cells in each skin biopsy isolated from all 17 UVB-treated patients and 9 control patients. Data of
UVB patients were grouped in patients with complete depletion (o1 LC per field, ‘‘complete’’) and patients with incomplete depletion (X1 LC per field,
‘‘incomplete’’). (d, e) The individual course of CD1aþ cells in skin biopsies. NS, not significant.
www.jidonline.org 181
M Kreutz et al.
UVB Decreases Graft-versus-Host Disease
Table 1. Patient characteristics and incidence of GvHD in UVB patients and control patients
GvHD
Donor1 Diagnosis Conditioning2
UVB dose
(J cm2)
CD1a +3
(cells per field) oDay 100 4Day 100 Time4
UVB patients: complete depletion
#1 sibl NHL FBM 0.34 0 0 3 Chronic 812
#2 sibl AML FBM 0.18 0 0 2 Chronic
#3 urd MM FBM 0.09 0 0 2 Chronic
#4 urd CLL FBM 0.18 0 NE NE
#5 sibl ALL FBM 0.24 0 0 3 Chronic 340
#6 sibl NHL RIC 0.19 0 0 0
#7 sibl NHL FBM 0.18 0.4 0 1 Chronic
#8 urd NHL FBM 0.18 0 1 3 190
#9 urd ALL FBM 0.24 0.2 0 4 234
Median 0.18 0 287
UVB patients: incomplete depletion
#10 sibl AML FBM 0.12 1 1 1 Chronic
#11 sibl AML FBM 0.18 5.5 0 0
#12 urd CLL FBM 0.12 5 0 0
#13 urd AML FBM 0.18 2 2 3 100
#14 urd CLL FBM 0.24 1 3 3 80
#15 sibl NHL FBM 0.22 2 4 3 Chronic 61
#16 urd CML FBM 0.20 6 2 1 Chronic
#17 sibl MM FBM 0.18 85 4 NE 31
Median 0.18 3.5 71
Control patients
#1 sibl MDS FBM 0 0.2 0 0
#2 sibl AML FBM 0 5 3 NE 55
#3 sibl MM FBM 0 2 3 3 Chronic 53
#4 sibl MM FBM 0 6 0 0
#5 urd MDS FBM 0 4 0 2 Chronic
#6 urd AML FBM 0 5 0 3 197
#7 sibl MM RIC 0 0.2 0 0
#8 urd AML RIC 0 9 1 1 Chronic
#9 sibl MM RIC 0 0 4 NE 63
Median 0 4 59
Abbreviations: ALL, acute lymphoblastic leukemia; AML, acute myelogenous leukemia; CLL, chronic lymphocytic leukemia; CML, chronic myelogenous
leukemia; GvHD, graft-versus-host disease; MDS, myelodysplastic syndrome; MM, myeloma; NE, not evaluable; NHL, non-Hodgkin lymphoma; RIC,
reduced intensity conditioning; sibl, sibling; urd, unrelated donor.
1Donor cells were obtained from sibl or urd.
2Patients received either conditioning consisting of fludarabin/bis-chloroethylnitrosourea or carmustine and melphalan (FBM) or were treated with
comparable RIC consisting of fludarabin and high-dose treosulfane or high-dose melphalan.
3Biopsies were taken between day 10 and day 15 and the number of CD1a+ cells was determined by immunohistochemical staining.
4Time to maximal severe GvHD was significantly (P=0.028) delayed in comparison to patients with incomplete depletion. Severe GvHD is defined as acute
(oday 100) or acute delayed (4day 100) GvHD grade 3–4 or severe chronic GvHD; chronic GvHD is graded according to the National Institutes of Health
as mild (1), moderate (2), or severe (3).
5The number of CD1a+ cells per field correlated to GvHD oday 100 in UVB patients (r=0.47, P=0.026).
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UVB-exposed patients showed significantly higher levels of
regulatory T cells compared with control patients (Figure 3a
and data not shown), whereas no other blood leukocyte
populations, e.g., CD8þ T cells, CD56þ NK cells, or
CD14þ monocytes, were significantly influenced by the
UVB treatment (Figure 3c and data not shown). However, the
percentage of circulating CD14þ cells was significantly
higher in the subgroup of UVB patients with complete
depletion (Figure 3d). No significant difference between both
subgroups was seen for regulatory T cells (Figure 3b).
Because the secretion of soluble factors may also be
involved in the protective effect of UVB irradiation, we next
investigated serum 25-hydroxyvitamin D3 levels and circulat-
ing cytokines. UVB patients had significantly higher 25-
hydroxyvitamin D3 serum levels, as compared with control
patients (Figure 4a), but similar levels of 1,25-dihydroxyvitamin
D3 and the complement factor C3c. With regard to circulating
cytokines, our results did not reveal any differences in IL-10
and macrophage colony-stimulating factor (M-CSF) serum
levels between control and UVB patients, but macrophage
migration inhibitory factor serum levels were significantly
reduced in the UVB group (Figure 4b). However, high M-CSF
serum levels significantly correlated with high 25-hydroxyvita-
min D3 serum levels (Figure 4c), suggesting that 25-hydroxy-
vitamin D3 might modulate M-CSF release. Furthermore, high
25-hydroxyvitamin D3 serum levels were especially found in
patients with low-grade GvHD 0–1 (Figure 4d).
DISCUSSION
GvHD is a potentially life-threatening complication of allo-
HCT, and several experimental and clinical efforts focus on
GvHD prevention. In a previous study, Yuksel et al. (2006)
tried to decrease the incidence and severity of GvHD by
peritransplant UVB irradiation. The results were disappointing
and revealed that UVB irradiation is detrimental to the
outcome of allo-HCT as seven of eight patients developed
severe acute GvHD including severe GvHD of the skin. In
striking contrast to these data, our irradiation protocol was well
tolerated in all patients. Most likely, the reason for this
discrepancy in the results is due to differences in the irradiation
protocol, as in this study UVB irradiation was initiated 10 days
before transplantation, thus interfering with conditioning.
Furthermore, Yuksel et al. (2006) used narrowband UVB,
whereas in our study patients were irradiated with broadband
UVB. Our data in mice have clearly shown that exposure to
UVC leads to massive recruitment of circulating monocytes to
the skin between 18hours and 4 days after irradiation (Merad
et al., 2004). It is thus likely that in this published study,
patients’ exposure to UVB at this early time point led to a
recruitment of host monocyte-derived DCs and to an increased
number of host DCs at the time of transplant, which may
explain the severe GvHD outcome in these patients.
In our protocol, UVB treatment decreased the number of LCs
in 15 out of 17 patients, and the number of CD1aþ epidermal
DCs correlated with GvHD severity in the UVB group. It has
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Figure 2. Enrichment of HLA-DRþ CD14þ dermal cells in UVB-irradiated patients. Six whole-body irradiations were given every second day with 75% of the
minimal erythemal dose starting from day 1 after allogeneic hematopoietic cell transplantation (allo-HCT). Control patients received the same conditioning
regime but no UVB irradiation. Skin biopsies were analyzed by immunohistochemical staining using anti-HLA-DR and anti-CD14. The absolute numbers of
CD14þ /HLA-DRþ cells (a), CD14þ /HLA-DR– cells (b), and CD14–/HLA-DRþ cells (c) show an enrichment of CD14þ /HLA-DRþ double-positive cells in
patients treated with UVB. Statistical analysis was performed with two-tailed Student’s t-test. NS, not significant.
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long been hypothesized that LCs are essential for the immune
response in the skin; however, murine model systems have
meanwhile shown that LCs are neither absolutely required for
contact hypersensitivity nor for T cell-mediated GvHD as long
as other antigen-presenting cells are present (Li et al., 2011).
Although our data in UVB-treated patients indicate an important
role of LCs in the development of GvHD, one patient in the
control group developed GvHD grade IV despite complete LC
depletion (0 CD1aþ cells per field). Therefore, the number of
LCs seems to be only one determinant for a lower GvHD risk in
UVB patients. It is most likely that other factors and/or cell types
contribute to the protective effect.
Dermal CD14þ cells dropped only significantly in
control patients who did not receive UVB, suggesting that
UVB restrains or recruits CD14þ cells in the dermis. This is
in line with data from Kang et al. (1994) showing that UVB
leads to an infiltration of immunosuppressive macrophages
to the dermis. These immunosuppressive dermal cells could
also contribute to the protective effect of UVB irradiation.
UVB-treated patients also had significantly higher numbers
of circulating CD4þ FoxP3þ regulatory T cells compared
with control patients, indicating that exposure to UVB facilitates
the reconstitution of the regulatory T compartment in
patients, whereas it does not influence the reconstitution of
other leukocyte populations in the blood. As T regulatory
cells are critical for the prevention of GvHD and can also
reverse established GvHD in a mouse model of allo-HCT
(Edinger et al., 2003; Gatza et al., 2008), part of the positive
effect of UVB could be mediated through the induction of
T regulatory cells. In mice, exposure to UVB leads to the
expansion of T regulatory cells, and UV-induced LC migra-
tion into lymph nodes is thought to be required for the
induction of a T regulatory cell response (Schwarz et al.,
2005). Furthermore, topically applied 1,25-dihydroxyvitamin
D3 has also been shown to induce the suppressive activity of
T regulatory cells in draining lymph nodes (Gorman et al.,
2007), suggesting that UVB-induced 25-hydroxyvitamin D3
in the skin may create a local immunosuppressive environ-
ment leading to the generation of tolerogenic DCs and
increased numbers of circulating regulatory T cells. Accordingly,
UVB irradiation also led to a significant increase in 25-hydroxy-
vitamin D3 serum levels, and lower 25-hydroxyvitamin D3
levels were associated with a higher risk of severe GvHD in
UVB patients. In contrast, all control patients without
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Figure 3. Flow cytometry analysis of immune cells in peripheral blood after UVB irradiation. Mononuclear cells were isolated from blood samples before
conditioning, after transplantation, and at two different time points after UVB irradiation (between days 14–22 and days 38–69). Stainings were performed with
CD4þ /Foxp3þ (a) and CD14þ (c) at each time point for each patient. Data of UVB patients were further analyzed and grouped in patients with complete
depletion of CD1aþ Langerhans cell (LC;o1 LC per field, ‘‘complete’’) and patients with incomplete depletion (X1 LC per field, ‘‘incomplete’’, b, d). Statistical
analysis was performed with two-tailed Student’s t-test. NS, not significant.
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UVB irradiation had low 25-hydroxyvitamin D3 levels after
allo-HCT. This is in line with data from our group showing
that 25-hydroxyvitamin D3 serum levels decrease after HCT
and remain low in patients who develop severe GvHD,
whereas they rise again in patients without GvHD (Kreutz
et al., 2004). As vitamin D analogs are known to prevent
acute GvHD in rat bone marrow transplantation (Pakkala
et al., 2001), and polymorphism of the vitamin D receptor
gene correlated with GvHD outcome (Middleton et al.,
2002), it is possible that the increase in 25-hydroxyvitamin
D3 release in UV-treated patients has a key role in the
modulation of GvHD in these patients. We also analyzed the
correlation between 25-hydroxyvitamin D3 serum levels and
circulating blood cells and cytokines, and found that
25-hydroxyvitamin D3 correlated positively with M-CSF
levels. These results are consistent with in vitro data showing
that 1,25-dihydroxyvitamin D3 increases M-CSF secretion
from human circulating monocytes in vitro (Kaneki et al.,
1994).
Altogether, our data show that low-dose UVB irradiation is
safe and well tolerated in allo-HCT patients. Our data also
show that successful depletion of LCs mediated by prophy-
lactic broadband UVB exposure correlates with a lower risk
for acute GvHD. Exposure to UVB also leads to elevated
serum levels of immunosuppressive factors such as 25-
hydroxyvitamin D3 and increased number of circulating T
regulatory cells. The exact contribution of these immunosup-
pressive mechanisms to GvHD outcome, as well as the exact
role of LCs in UVB-mediated immunosuppression, remains to
be examined. These results suggest that prophylactic UVB
exposure at the time of transplant should be explored as a
clinical strategy to prevent acute GvHD. Further studies are
also required to optimize the timing and dosage of UVB to
achieve complete LC depletion in all patients.
PATIENTS AND METHODS
Patients
All patients were included after giving written informed consent.
The study had been approved by the local ethics committee at
the University Medical Centre of Regensburg and was conducted
according to the Declaration of Helsinki Principles.
A total of 17 patients received UVB prophylaxis: 8 patients
were female and 9 were male; the median age at SCT was 54 years
(range 34–64 years). Underlying diseases were acute myelogenous
leukemia, acute lymphoblastic leukemia, chronic myelogenous
leukemia, low-grade lymphoma or chronic lymphocytic leukemia,
NSa c
db NS
NS100,000
10,000
1,000
100
10Cy
to
kin
e 
(pg
 m
l–1
)
1
0.1
NS
NS
NS
NS
NS ****
*
125 300
1.25 (OH)2 D
3
 (pmol l
–1)
C3c (mg dl
–1)
250
200
150
100
50
0
100
75
50
25
0
Before UVB Control
25(OH)D3 1.25(OH)2D3 C3c
IL-10
2,500
r = 0.53
75 *
50
25
0
Be
for
e 
co
nd
Aft
er 
co
nd
Aft
er 
UV
B
Be
for
e 
co
nd
Aft
er 
co
nd
Aft
er 
UV
B
P = 0.052,000
1,500
1,000
500
0
0 20 40
25(OH) D3
GvHD 0–1 GvHD 2–4
60 80
M
-C
SF
 (p
g m
l–1
)
25
(O
H)
D 3
 
(nm
ol 
l–1
)
M-CSF MIF
Before UVB Control Before UVB Control
Before UVB Control Before UVB Control Before UVB Control
25
(O
H)
D 3
 
(nm
ol 
l–1
)
NS
NS
**
NS
NS
***
Figure 4. Determination of cytokines, 25-hydroxyvitamin D3 (25(OH)D3), 1,25-dihydroxyvitamin D3 (1,25(OH)2D3), and C3c in the serum of UVB and
control patients. Serum samples were collected before conditioning (cond), after transplantation, and around day 14 after UVB exposure. Complement C3c and
vitamin D metabolites were analyzed with a routine procedure in the Department of Clinical Chemistry, University of Regensburg (a). Serum macrophage
migration inhibitory factor (MIF), M-CSF, and IL-10 levels were measured by commercially available ELISA (b). Statistical analysis was performed with two-tailed
Student’s t-test. Graph (c) shows the correlation between 25-hydroxyvitamin D3 and M-CSF serum levels at day 14 after UVB irradiation (r¼ 0.53, P¼ 0.05). For
further analysis UVB patients were grouped according to their acute graft-versus-host disease (GvHD) severity (GvHD 0–1 vs. 2–4, d). M-CSF, macrophage
colony-stimulating factor; NS, not significant.
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high-grade lymphoma (non-Hodgkin lymphoma) and myeloma (see
Table 1). All patients were in a more advanced stage of disease
(only partial remission of leukemia or X2nd complete remission).
Donors were HLA-identical siblings in nine, 10/10 antigen-matched
unrelated donors in six, and 9/19 antigen-matched unrelated donors
in two. Patients received reduced intensity conditioning consisting
of fludarabin/bis-chloroethylnitrosourea or carmustine and melphalan
(FBM) as described previously (Table 1, Marks et al., 2008);
four patients were treated with reduced intensity conditioning
consisting of fludarabin (30mgm2 for 5 days) and high-dose
treosulfane (14 gm2 for 3 days) or high-dose mephalan (Table 1).
Immunosuppressive prophylaxis included ciclosporin starting from
day 2, and mycophenolate mofetil was started at the day of SCT
6hours after infusion of peripheral blood stem cells. Antithymocyte
globulin was used as pretransplant serotherapy in a dose of
10mg kg1 for 3 days in all unrelated donors. All patients received
peripheral blood stem cell grafts; the mean number of CD34 cells
infused was 4.8 (±1.2) 106 per kg. Patients receiving the identical
conditioning protocol without additional UVB exposure served
as controls.
Acute and chronic GvHD were graded and staged according
to clinical criteria as previously described (Marks et al., 2008).
To summarize the combined effects on acute, delayed acute, and
chronic GvHD, severe GvHD was defined as either acute GvHD
grade III or IV or severe chronic GvHD, and time to maximal
occurrence of severe GvHD was calculated for all patients.
Irradiation protocol
The patients’ individual minimal erythemal dose was determined
1 day before stem cell transplantation by a sequence of seven trial
exposures made on normal skin on the buttocks using incremental
series of UVB irradiations (UVB doses: 14-20-28-40-56-80 and
112mJ cm2). The minimal erythemal dose was taken to be the dose
given to the aperture showing just perceptible erythema.
One day after allogeneic stem cell transplantation, broad-
band UVB (wavelength 280–320nm) therapy was started using a
whole-body irradiation cabinet (UV 7001K Waldmann Medizin-
technik, Villingen-Schwenningen, Germany) containing 13 Wald-
mann low-pressure lamps (F85/100 W–UV21) for broadband UVB
irradiation. The cabinet contains UV-sensor systems that automati-
cally and continuously measure the light intensity (mWcm2) and
the light dose (J cm2). Treatment was given every second day for a
total of six whole-body UVB irradiations with 75% of the minimal
erythemal dose.
Skin biopsies and immunohistochemistry/immunofluorescence
Punch biopsies (5mm) were taken from clinically normal skin from
the medial side of the upper arm before conditioning, on the day
before transplantation and on day 12 after transplantation after the
last UVB irradiation. Biopsies from control patients not receiving
UVB irradiation were taken at days 10–14.
Immunohistochemistry of epidermal cells was performed with
formalin-fixed paraffin-embedded 2-mm thick sections using CD1a
(Clone 010, Zytomed) at a previously titrated optimal concentration
and the Zytochem Plus Broad Spectrum HRP-Kit (Zytomed, Berlin,
Germany). Sections were counterstained with AEC (Dako, Hamburg,
Germany). Negative controls were performed by omitting incubation
with the primary antibody. Immunoreactive cells in at least five
randomly selected areas were counted by two blinded investigators
and expressed as positive cells per high-power field.
Immunofluorescence staining of dermal cells was performed on
6-mm frozen skin sections using rabbit polyclonal anti-CD14 (AbCam,
San Francisco, CA), mouse anti-HLA-DR (Dako), donkey anti-mouse
biotin, donkey anti-rabbit FITC, and Streptavidine-Cy5 (Jackson
Immunoresearch, West Grove, PA). Staining with secondary antibodies
alone was used as negative control. Nuclear cells were counted in 10
randomly selected fields.
Flow cytometry of mononuclear cells
Mononuclear cells were isolated from freshly drawn blood samples
by density gradient centrifugation over Ficoll/Hypaque (Biochrom
AG, Berlin, Germany). Stainings were performed with 2–10 105 cells
per 100ml PBS/2% FCS using the following antibodies at previously
titrated optimal concentrations: CD3-FITC (SK7), CD3-APC (UCHT1),
CD4-FITC (SK3), CD8-APC (SK1), CD14-PE (M0P9), CD19-FITC
(4G7), CD25-PE and -APC (2A3), and CD56-PE (B159; all from BD
Biosciences, Heidelberg, Germany). Propidium iodide (2.5 mgml1)
was added to unfixed samples to exclude dead cells. FOXP3 stains
were performed with PE-conjugated antibodies (PCH101) and respec-
tive isotype control from eBioscience (San Diego, CA) according to
the manufacturer’s instruction. Flow cytometric data were acquired
on a FACSCalibur (BD Biosciences) and analyzed with FlowJo software
(Treestar, Ashland, OR).
Determination of cytokines and vitamin D3 metabolites
in serum
Blood samples were taken before allo-HCT and at day 14. Cytokines
(macrophage migration inhibitory factor-1, M-CSF, and IL-10) were
measured in the serum samples by commercially available ELISA
(R&D Systems, Abingdon, UK). Complement C3c was measured by
nephelometry and vitamin D metabolites were analyzed by radio-
immunoassay in the Department of Clinical Chemistry, University of
Regensburg, Germany.
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